How Different GLP-1 Drugs Reshape Their Receptor in Fundamentally Different Ways | Research

The takeaway

Molecular simulations reveal that biased and balanced GLP-1 receptor agonists produce distinct receptor shapes, explaining why different drugs activate different signaling pathways from the same target.

3 distinct binding modes
Each GLP-1 agonist type — biased small molecule, balanced small molecule, and peptide — reshaped the receptor differently at the atomic level

What the researchers found

Using molecular dynamics simulations, researchers revealed how three different types of GLP-1 receptor agonists — a biased small molecule (CHU-128), a balanced small molecule (danuglipron), and a balanced peptide (Peptide 19) — each produce distinct structural changes in the receptor. Each ligand induced unique helix packing arrangements and conformational dynamics, explaining at the atomic level why different drugs activate different downstream signaling pathways from the same receptor.

The simulations showed that biased versus balanced agonists produce fundamentally different receptor shapes, which determines whether the receptor preferentially signals through G-proteins, β-arrestin, or both.

Why it matters

GLP-1 drugs like semaglutide and tirzepatide are blockbuster medications, but they all cause side effects partly because they activate multiple signaling pathways at once. Understanding exactly how different agonists reshape the GLP-1 receptor could enable scientists to design 'biased' drugs that activate only the pathways needed for therapeutic benefit (like blood sugar control) while avoiding those that cause nausea or other side effects. This study provides the atomic-level blueprint for that kind of rational drug design.

The numbers in context

3 agonists compared · CHU-128 (biased small molecule) · danuglipron (balanced small molecule) · Peptide 19 (balanced peptide) · all-atom molecular dynamics simulations

How the study worked

Computational study using all-atom molecular dynamics (MD) simulations. Researchers modeled the GLP-1 receptor in complex with three prototypical agonists representing different binding modes and signaling profiles. Simulations tracked how each ligand changes the receptor's three-dimensional structure over time, revealing the conformational dynamics that determine signaling pathway preference.

Who was studied

Not applicable (computational molecular dynamics study)

What this study cannot tell us

Purely computational — no experimental validation of the predicted conformational states. MD simulations depend on the accuracy of force fields and starting structures. The simulated timescales may not capture all biologically relevant conformational changes. Real cellular environments with lipid membranes, G-proteins, and other partners add complexity not fully captured in simulation.

How to read the evidence

Preliminary — this is a computational modeling study with no experimental validation. While molecular dynamics simulations provide valuable mechanistic hypotheses, the predicted conformational states need to be confirmed by experimental methods like cryo-EM or functional assays. The insights are theoretical but scientifically grounded.

When this study was published

Published in 2025. This is very recent work reflecting the cutting edge of GLP-1 receptor structural pharmacology, building on the explosion of cryo-EM structures and computational methods in the field.

The bigger picture

The GLP-1 drug market is projected to exceed $100 billion, and the race is on to develop next-generation agonists that are more effective with fewer side effects. The concept of 'biased agonism' — designing drugs that selectively activate beneficial pathways while avoiding harmful ones — is one of the most promising strategies. This computational study provides the structural foundation for that approach, showing exactly which receptor conformations lead to which signaling outcomes. As both peptide and small-molecule GLP-1 drugs compete for market share, this kind of mechanistic insight could determine which designs win.

Questions still open

Can the conformational insights from these simulations be used to design a GLP-1 agonist that eliminates nausea while maintaining weight loss efficacy?
Do the predicted biased signaling profiles match experimental measurements of pathway activation?
How does the natural peptide GLP-1(7-36) compare to these three agonists in terms of receptor conformational dynamics?

Common questions

What is biased agonism and why does it matter for GLP-1 drugs?

Biased agonism means a drug activates some of the receptor's downstream signals but not others. For GLP-1 drugs, this matters because the same receptor controls beneficial effects (blood sugar reduction, appetite suppression) and unwanted side effects (nausea, vomiting). A biased drug could potentially deliver the benefits while avoiding the downsides by only activating the right pathways.

Why use computer simulations instead of lab experiments?

Molecular dynamics simulations let scientists watch how a drug reshapes a receptor at the atomic level — something no microscope can do in real time. While simulations need experimental validation, they can rapidly screen hypotheses about why different drugs work differently, guiding which experiments are most worth running. It's much faster and cheaper than trial-and-error in the lab.

Read the original research

Exploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R.

Molecules (Basel, Switzerland), 30(15)

View on PubMed ↗Publisher’s paper ↗

Citation

Xu, Marc; Vogel, Horst; Yuan, Shuguang. (2025). Exploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R.. Molecules (Basel, Switzerland), 30(15). https://doi.org/10.3390/molecules30153216